0GP7
:LSE

Add to watchlist
11,00 kr
Last updated:09/07/2021
0GP7: LSE
11,00 kr
Medivir AB Series B

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma…

P/E ratio
-
vs. 0.00x forward
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
Company profile
CEO
Not defined
Website
Market capitalization
Micro (294.00M)